Cargando…
Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib
BACKGROUND: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180504/ https://www.ncbi.nlm.nih.gov/pubmed/25279299 http://dx.doi.org/10.1186/2193-1801-3-507 |
_version_ | 1782337232810541056 |
---|---|
author | Agbarya, Abed Melamed-Frank, Meira Kaidar-Person, Orit Goldberg-Cohen, Ilana Nasrallah, Haitam Wollner, Mira Bar, Jair Rennert, Gad Lejbkowicz, Flavio |
author_facet | Agbarya, Abed Melamed-Frank, Meira Kaidar-Person, Orit Goldberg-Cohen, Ilana Nasrallah, Haitam Wollner, Mira Bar, Jair Rennert, Gad Lejbkowicz, Flavio |
author_sort | Agbarya, Abed |
collection | PubMed |
description | BACKGROUND: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exon 19 insertions mutations are rare, and response to TKIs is still unclear. CASE DESCRIPTION: A young Arab patient was diagnosed with metastatic disease of NSCLC harboring an exon 19 insertion of 18 nucleotides. The patient showed a very impressive clinical and radiological response within few weeks treatment with TKI agent. DISCUSSION AND EVALUATION: To our best knowledge, This case is the first case in Arab woman and one of few cases described in the literature with this rare mutation responding to TKIs. CONCLUSIONS: Treatment with TKIs should be the standard choice in patients with metastatic disease NSCLC. |
format | Online Article Text |
id | pubmed-4180504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-41805042014-10-02 Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib Agbarya, Abed Melamed-Frank, Meira Kaidar-Person, Orit Goldberg-Cohen, Ilana Nasrallah, Haitam Wollner, Mira Bar, Jair Rennert, Gad Lejbkowicz, Flavio Springerplus Case Study BACKGROUND: Most patients with non-small cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Advanced NSCLC that contains characteristic mutations in epidermal growth factor receptor (EGFR) are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs). EGFR exon 19 insertions mutations are rare, and response to TKIs is still unclear. CASE DESCRIPTION: A young Arab patient was diagnosed with metastatic disease of NSCLC harboring an exon 19 insertion of 18 nucleotides. The patient showed a very impressive clinical and radiological response within few weeks treatment with TKI agent. DISCUSSION AND EVALUATION: To our best knowledge, This case is the first case in Arab woman and one of few cases described in the literature with this rare mutation responding to TKIs. CONCLUSIONS: Treatment with TKIs should be the standard choice in patients with metastatic disease NSCLC. Springer International Publishing 2014-09-09 /pmc/articles/PMC4180504/ /pubmed/25279299 http://dx.doi.org/10.1186/2193-1801-3-507 Text en © Agbarya et al.; licensee Springer. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Case Study Agbarya, Abed Melamed-Frank, Meira Kaidar-Person, Orit Goldberg-Cohen, Ilana Nasrallah, Haitam Wollner, Mira Bar, Jair Rennert, Gad Lejbkowicz, Flavio Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title | Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title_full | Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title_fullStr | Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title_full_unstemmed | Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title_short | Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib |
title_sort | getting out of a wheelchair: an uncommon insertion mutation in exon 19 of egfr responsive to erlotinib |
topic | Case Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180504/ https://www.ncbi.nlm.nih.gov/pubmed/25279299 http://dx.doi.org/10.1186/2193-1801-3-507 |
work_keys_str_mv | AT agbaryaabed gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT melamedfrankmeira gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT kaidarpersonorit gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT goldbergcohenilana gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT nasrallahhaitam gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT wollnermira gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT barjair gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT rennertgad gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib AT lejbkowiczflavio gettingoutofawheelchairanuncommoninsertionmutationinexon19ofegfrresponsivetoerlotinib |